Market Cap 182.28M
Revenue (ttm) 18.00M
Net Income (ttm) -47.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -265.17%
Debt to Equity Ratio 0.13
Volume 783,900
Avg Vol 993,690
Day's Range N/A - N/A
Shares Out 105.36M
Stochastic %K 44%
Beta 0.04
Analysts Strong Sell
Price Target $8.25

Company Profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 88 166 7000
Address:
Zernikedreef 9, Leiden, Netherlands
G101SPM
G101SPM Jul. 13 at 5:18 PM
#INSIDERS $AVO 10% owner Globalharvest Holdings Venture bought 592,957 shares at $13.04 - $13.35 worth approximately $7.9 mln (transaction date 7/9). $CMC President / Chief Executive Officer bought 8,230 shares at $61.30 worth approximately $504K (transaction date 7/10). CV 10% owner bought 81,300 shares at $6.09 worth approximately $495K (transaction date 7/8). $PRQR Chief Executive Officer bought 150,000 shares at $1.74 worth approximately $261K (transaction date 7/9). $PBF 10% owner Control Empresarial de Capitales S.A. de C.V. sold 650,000 Class A Common Shares worth approximately $34.2 mln (transaction dates 7/8-7/9). $SAFT 10% owner sold 2,650 shares worth approximately $203K (transaction date 7/9).
0 · Reply
Bobfree
Bobfree Jul. 13 at 4:33 PM
$PRQR CEO is once again putting money where my mouth is. Extremely bullish in this thing after that engagement data. The institutions and insiders are too.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 13 at 2:05 PM
$PRQR CEO purchased 150,000 shares at $1.74 for a total of $261,000. de Boer Daniel Anton now owns 300,000 shares. https://ceo-buys.com
0 · Reply
ACH50
ACH50 Jul. 13 at 12:18 PM
$PRQR next gen RNA editing company in the making
0 · Reply
ACH50
ACH50 Jul. 13 at 12:17 PM
0 · Reply
FilingTracker
FilingTracker Jul. 13 at 12:01 PM
$PRQR CEO purchased additional shares: https://filingtracker.ai/filing/1612940/0001104659-26-082890
0 · Reply
Filvul
Filvul Jul. 9 at 6:41 AM
$PRQR CEO Daniel de Boer bought 150,000 shares at $1.59 with personal capital on July 7, 2026 — filed just yesterday Director Bart Filius bought 150,000 shares at $1.54 on June 26, the day after the AX-0810 data Zero open-market sales in the last six months.. Total insider buys: $469,500 — all discretionary, none tax-driven:)
1 · Reply
struminbanjobio
struminbanjobio Jul. 8 at 9:07 PM
$PRQR maybe I should buy more too
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 8 at 9:00 PM
$PRQR CEO purchased 150,000 shares at $1.59 for a total of $238,500. de Boer Daniel Anton now owns 150,000 shares. https://ceo-buys.com
0 · Reply
ehpats
ehpats Jul. 8 at 8:46 PM
$PRQR CEO this time, 150k shares. That gives me more confidence than the director buying shares last week.
0 · Reply
Latest News on PRQR
ProQR Therapeutics Slides: Conference presentation

Jun 25, 2026, 7:00 AM EDT - 18 days ago

ProQR Therapeutics Slides: Conference presentation


ProQR Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

ProQR Therapeutics Earnings release: Q1 2026


ProQR Therapeutics management to meet with Cantor Fitzgerald

2026-04-08T20:45:41.000Z - 3 months ago

ProQR Therapeutics management to meet with Cantor Fitzgerald


ProQR Therapeutics management to meet with Oppenheimer

2026-04-08T20:40:37.000Z - 3 months ago

ProQR Therapeutics management to meet with Oppenheimer


ProQR Therapeutics Transcript: Status update

Apr 8, 2026, 10:00 AM EDT - 3 months ago

ProQR Therapeutics Transcript: Status update


ProQR Therapeutics Press release: Status update

Apr 8, 2026, 10:00 AM EDT - 3 months ago

ProQR Therapeutics Press release: Status update


ProQR Therapeutics Slides: Status update

Apr 8, 2026, 10:00 AM EDT - 3 months ago

ProQR Therapeutics Slides: Status update


ProQR Therapeutics assumed with an Outperform at Oppenheimer

2026-03-12T11:46:03.000Z - 4 months ago

ProQR Therapeutics assumed with an Outperform at Oppenheimer


ProQR Announces Year End 2025 Operating and Financial Results

Mar 12, 2026, 7:00 AM EDT - 4 months ago

ProQR Announces Year End 2025 Operating and Financial Results


ProQR Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

ProQR Therapeutics Annual report: Q4 2025


ProQR Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

ProQR Therapeutics Earnings release: Q4 2025


ProQR Announces Planned Changes to Board Composition

Feb 9, 2026, 8:00 AM EST - 5 months ago

ProQR Announces Planned Changes to Board Composition


ProQR Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 9:30 AM EST - 8 months ago

ProQR Therapeutics Earnings release: Q3 2025


ProQR Therapeutics Transcript: Study Update

Nov 3, 2025, 10:00 AM EST - 9 months ago

ProQR Therapeutics Transcript: Study Update


ProQR Therapeutics Press release: Study Update

Nov 3, 2025, 10:00 AM EST - 9 months ago

ProQR Therapeutics Press release: Study Update


ProQR Therapeutics Slides: Study Update

Nov 3, 2025, 10:00 AM EST - 9 months ago

ProQR Therapeutics Slides: Study Update


ProQR Therapeutics receives CTA authorization for AX-0810

2025-10-20T12:05:08.000Z - 9 months ago

ProQR Therapeutics receives CTA authorization for AX-0810


ProQR Therapeutics management to meet with Citizens JMP

2025-10-16T16:15:25.000Z - 9 months ago

ProQR Therapeutics management to meet with Citizens JMP


ProQR Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 9:30 AM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q2 2025


ProQR Therapeutics sees cash runway into mid-2027

2025-08-07T11:32:17.000Z - 1 year ago

ProQR Therapeutics sees cash runway into mid-2027


ProQR Announces Upcoming Presentation at RNA Editing Summit

Jul 28, 2025, 8:00 AM EDT - 1 year ago

ProQR Announces Upcoming Presentation at RNA Editing Summit


ProQR Therapeutics Earnings release: Q1 2025

May 7, 2025, 6:00 PM EDT - 1 year ago

ProQR Therapeutics Earnings release: Q1 2025


ProQR Therapeutics Annual report: Q4 2024

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Annual report: Q4 2024


ProQR Therapeutics Press release: Q4 2024

Mar 13, 2025, 1:30 PM EDT - 1 year ago

ProQR Therapeutics Press release: Q4 2024


ProQR Announces Year End 2024 Operating and Financial Results

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2024 Operating and Financial Results


ProQR Therapeutics Transcript: AGM 2024

Dec 11, 2024, 10:00 AM EST - 1 year ago

ProQR Therapeutics Transcript: AGM 2024


ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist


ProQR Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 9:30 AM EST - 1 year ago

ProQR Therapeutics Earnings release: Q3 2024


ProQR Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:21 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q2 2024


ProQR Therapeutics Transcript: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Transcript: Status Update


ProQR Therapeutics Press release: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Press release: Status Update


ProQR Therapeutics Slides: Status Update

May 9, 2024, 8:00 AM EDT - 2 years ago

ProQR Therapeutics Slides: Status Update


ProQR Therapeutics Earnings release: Q1 2024

May 9, 2024, 2:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q1 2024


ProQR Announces Year End 2023 Operating and Financial Results

Mar 13, 2024, 7:00 AM EDT - 2 years ago

ProQR Announces Year End 2023 Operating and Financial Results


ProQR Therapeutics Annual report: Q4 2023

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Annual report: Q4 2023


ProQR Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 6:00 AM EDT - 2 years ago

ProQR Therapeutics Earnings release: Q4 2023


ProQR Therapeutics Earnings release: Q3 2023

Nov 7, 2023, 5:00 AM EST - 2 years ago

ProQR Therapeutics Earnings release: Q3 2023


ProQR Therapeutics Earnings release: Q2 2023

Aug 3, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q2 2023


ProQR Therapeutics Earnings release: Q1 2023

May 16, 2023, 5:00 AM EDT - 3 years ago

ProQR Therapeutics Earnings release: Q1 2023


ProQR Announces Upcoming Investor Conferences in April and May

Apr 20, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Upcoming Investor Conferences in April and May


G101SPM
G101SPM Jul. 13 at 5:18 PM
#INSIDERS $AVO 10% owner Globalharvest Holdings Venture bought 592,957 shares at $13.04 - $13.35 worth approximately $7.9 mln (transaction date 7/9). $CMC President / Chief Executive Officer bought 8,230 shares at $61.30 worth approximately $504K (transaction date 7/10). CV 10% owner bought 81,300 shares at $6.09 worth approximately $495K (transaction date 7/8). $PRQR Chief Executive Officer bought 150,000 shares at $1.74 worth approximately $261K (transaction date 7/9). $PBF 10% owner Control Empresarial de Capitales S.A. de C.V. sold 650,000 Class A Common Shares worth approximately $34.2 mln (transaction dates 7/8-7/9). $SAFT 10% owner sold 2,650 shares worth approximately $203K (transaction date 7/9).
0 · Reply
Bobfree
Bobfree Jul. 13 at 4:33 PM
$PRQR CEO is once again putting money where my mouth is. Extremely bullish in this thing after that engagement data. The institutions and insiders are too.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 13 at 2:05 PM
$PRQR CEO purchased 150,000 shares at $1.74 for a total of $261,000. de Boer Daniel Anton now owns 300,000 shares. https://ceo-buys.com
0 · Reply
ACH50
ACH50 Jul. 13 at 12:18 PM
$PRQR next gen RNA editing company in the making
0 · Reply
ACH50
ACH50 Jul. 13 at 12:17 PM
0 · Reply
FilingTracker
FilingTracker Jul. 13 at 12:01 PM
$PRQR CEO purchased additional shares: https://filingtracker.ai/filing/1612940/0001104659-26-082890
0 · Reply
Filvul
Filvul Jul. 9 at 6:41 AM
$PRQR CEO Daniel de Boer bought 150,000 shares at $1.59 with personal capital on July 7, 2026 — filed just yesterday Director Bart Filius bought 150,000 shares at $1.54 on June 26, the day after the AX-0810 data Zero open-market sales in the last six months.. Total insider buys: $469,500 — all discretionary, none tax-driven:)
1 · Reply
struminbanjobio
struminbanjobio Jul. 8 at 9:07 PM
$PRQR maybe I should buy more too
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 8 at 9:00 PM
$PRQR CEO purchased 150,000 shares at $1.59 for a total of $238,500. de Boer Daniel Anton now owns 150,000 shares. https://ceo-buys.com
0 · Reply
ehpats
ehpats Jul. 8 at 8:46 PM
$PRQR CEO this time, 150k shares. That gives me more confidence than the director buying shares last week.
0 · Reply
johnnygogogo
johnnygogogo Jul. 8 at 6:59 PM
$PRQR more insider buys dumplings
0 · Reply
FutureInvesting777
FutureInvesting777 Jul. 8 at 3:03 PM
$PRQR one may assume that’s every time SP goes up, the “investor” with the so 3.03 millions shares sells a few shares.
0 · Reply
Filvul
Filvul Jul. 8 at 4:53 AM
$PRQR Oppenheimer Reaffirms Their Buy Rating on ProQR (PRQR) - TipRanks.com https://share.google/0S03W3Y8IG4jHLW7Y
1 · Reply
dirkfrank
dirkfrank Jul. 8 at 4:52 AM
$PRQR oppenheimer report?
0 · Reply
Filvul
Filvul Jul. 7 at 2:46 PM
$PRQR Oppenheimer set a new price 9$
3 · Reply
NOONEUKNOW
NOONEUKNOW Jul. 7 at 2:36 PM
$PRQR Oppenheimer analyst Kostas Biliouris maintains $PROQR Therapeutics (PRQR.US)$ with a buy rating, and adjusts the target price from $9 to $1.81.
1 · Reply
NOONEUKNOW
NOONEUKNOW Jul. 7 at 2:35 PM
$PRQR Oppenheimer analyst Kostas Biliouris maintains $PROQR Therapeutics (PRQR.US)$ with a buy rating, and adjusts the target price from $9 to $1.81.
0 · Reply
FutureInvesting777
FutureInvesting777 Jul. 7 at 1:36 PM
$PRQR hopefully the “investor” does not dump the 3.03 or so million shares all at once :) :)
1 · Reply
kd1313
kd1313 Jul. 6 at 8:47 PM
$PRQR Schwab requires me to call broker for a buy order…. Someone short shares?
1 · Reply
Filvul
Filvul Jul. 2 at 2:12 PM
0 · Reply
Filvul
Filvul Jul. 2 at 11:03 AM
0 · Reply
justfacts1
justfacts1 Jul. 1 at 5:20 PM
$PRQR first open market buy in company history!
1 · Reply